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ABSTRACT. Background and aims: Although in-
flammatory and hormonal markers have been associ-
ated with further functional adverse outcomes in com-
munity-dwelling seniors, these markers have not been
studied from this perspective in acutely ill older pa-
tients. This prospective study was designed to deter-
mine whether biological markers can improve the pre-
dictive value of a clinical screening tool to assess the
risk of functional decline in hospitalized older pa-
tients. Methods: Patients aged 75 years and over ad-
mitted for hip fracture, acute heart failure or infection
(n=118) were recruited. The clinical screening tool
SHERPA was filled in on admission, with concomitant
measurement of interleukin-6 (IL-6), insulin-like growth
factor 1 (IGF-1), C-reactive protein (CRP), white blood
cells, urea, albumin, pre-albumin and total choles-
terol. Functional decline was defined as a decrease of
one point in the activities of daily living scale between
pre-admission and 3-month post-discharge status. We
compared the discrimination calibration of SHERPA vs
SHERPA+, a logistic regression model including
SHERPA and selected biomarkers. Results: Three
months after discharge, functional decline had oc-
curred in 46 patients. IL-6 and IGF-1 were selected,
since their levels were significantly different between
decliners and non-decliners, and were included in the
new logistic regression model SHERPA+. Areas un-
der the ROC curve [95% CI] for functional decline
prediction were 0.73 [0.63-0.81] for SHERPA vs
0.79 [0.69-0.86] for SHERPA+ (p=0.14). However,
SHERPA+ was better calibrated, as the average pre-
dicted risk of functional decline within subgroups
matched the proportion which actually underwent
functional decline (Brier score=0.185). Since func-
tional decline was higher in patients with hip fracture,
the SHERPA+ model was challenged by including the
diagnosis. Only SHERPA, IGF-1 and diagnosis were
significantly associated with functional decline. Con-
clusions: Selected biological markers may marginal-
ly improve the clinical prediction of post-discharge
functional decline in hospitalized patients, and may
allow to stratify them appropriately. The predictive
value of these biomarkers is not fully independent of
disease status. Further studies are needed to con-
firm these results in a cohort representative of older
patients admitted through the emergency depart-
ment.
(Aging Clin Exp Res 2011; 23: 106-111)
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INTRODUCTION
Identification of elderly subjects at risk of functional de-
cline is a major public health concern since targeted
geriatric interventions may prevent or limit functional
loss in both community-dwelling subjects and hospitalized
patients (1, 2). Functional recovery after an acute health
event may indeed contribute toward identifying frail old-
er patients (3, 4).
In the hospital setting, several screening tools predict-
ing functional decline after hospitalization have been pro-
posed (5-7). A recent systematic review compared sever-
al of them and, since none had sufficient predictive valid-
ity, the authors recommended to test several other pro-
cedures to improve the predictive value of these instru-
ments (8). Various physiological markers have been sug-
gested as valuable candidates for this purpose (9, 10).












Inflammation and neuroendocrine dysregulation have
been proposed as impaired physiological mechanisms
involved in the process of functional decline (11). In
community-dwelling seniors, peripheral blood markers of
inflammation, including interleukin-6 (IL-6), C-reactive
protein (CRP) and albumin, have been independently
correlated with functional adverse outcomes in several lon-
gitudinal cohort studies. Ferrucci et al. demonstrated a re-
lationship between inflammation and the development of
further disability in activities of daily living (ADL) (12, 13).
In another study, a summary score including several pe-
ripheral blood markers of inflammation (IL-6, albumin,
cholesterol, CRP) was associated with increased risk of
functional decline at three years (14). Alterations in hor-
monal regulations have also been proposed as mediators
of functional decline in older people. Insulin-like growth
factor-1 (IGF-1) declines in normal aging (15) and is
mainly regulated by nutritional status (16). According to
Cappola et al., IL-6 and IGF-1 acted synergistically to pro-
mote disability and mortality (9).
However, few studies have investigated the potential in-
terest of these biomarkers in hospitalized older patients.
The aim of this study was to determine whether selected
inflammatory and hormonal markers, measured early
after admission, can improve the predictive validity of a
clinical tool screening for the risk of functional decline fol-
lowing hospitalization of older patients.
METHODS
Participants
Participants were recruited among patients 75 years old
and over, hospitalized in acute medical and surgical
wards of a tertiary care university hospital, through the
emergency department. To reduce heterogeneity and
address specific models of inflammatory challenges, we se-
lected patients with one of the following admission diag-
noses: hip fracture after surgery, acute heart failure, or
documented infection (with bacteriological and/or radio-
logical proof). Patients were excluded if they had taken
steroid or non-steroid anti-inflammatory drugs one week
before inclusion, had cancer, had stayed in hospital with-
in the previous two weeks, were admitted for intensive or
palliative care, or were completely dependent in activities
of daily living (ADL). Informed consent was obtained
from each participant, or the caregiver when patients were
unable to answer. The ethics committee of the hospital
approved the study.
Data collection
Each participant was assessed within 72 hours of ad-
mission by two trained interviewers. In case of deafness,
impaired cognitive status or institutionalization, ques-
tions were asked to the referent person (family member,
nursing home staff). Functional status was assessed at
baseline level (2 weeks before admission) with a modified
Katz index of ADL (17). Each of the 6 ADL (bathing,
dressing, transferring, toileting, being continent, eating)
was rated 1 if the patient could perform the activity and
0 if the patient needed assistance. Comorbidity was rat-
ed with the Cumulative Rating Scale adapted for geriatrics
(CIRS-G), which assesses 14 categories of organ sys-
tems (severity of impairment: 0 to 4; total score: 0-56;
severity index= total score/number of categories: 0-4)
(18). The risk of functional decline 3 months after dis-
charge was assessed by SHERPA (Score Hospitalier
d’Evaluation du Risque de la Perte d’Autonomie), a 5-
item predictive tool including age, history of falls in the
previous year, cognitive function, performance in instru-
mental ADL (iADL) 2 weeks before admission and self-rat-
ed health (5). Cognitive function was assessed with a
shortened form of the Mini Mental Status Examination
(21-item MMSE), excluding the 9 last items for practical
reasons and distinguishing patients in 2 groups (<15/21
and ≥15/21) (19). The 7 iADL assessed were telephon-
ing, using transportation, preparing meals, doing house-
work, taking medications and managing finances, and
were rated 1 (independent) or 0 (needing assistance) (7
points) (20). SHERPA ranges from 0 to 11.5 (low to high
risk of functional decline) and was chosen because it
was developed in a comparable Belgian population and
showed similar performance compared with other tools
predicting functional decline (8).
Biological variables
Blood sample were taken after a 12-h overnight fast
within 96 hours of admission, and were delivered to the
central laboratory for measurement of C-reactive protein
(CRP), white blood cells, urea, albumin, pre-albumin and
total cholesterol. Aliquots were stored at -80°C until
analysis. Interleukin-6 and IGF-1 were measured in du-
plicate by an enzyme-linked immunosorbent assay (ELISA)
(Biosource, Nivelles, Belgium). The minimal detectable
concentrations for IL-6 and IGF-1 were respectively 2
pg/mL and 4.9 ng/mL.
Outcomes
Functional status was reassessed 3 months after dis-
charge by phone contact, and functional decline was
defined as a loss of at least 1 point on the ADL scale be-
tween premorbid status (2 weeks before admission) and 3-
month post-discharge evaluation.
Statistical analysis
Comparisons between groups used the chi-square test
for categorical variables and the Wilcoxon rank sum test for
numerical variables. Each individual biological variable
(CRP, white blood cells, urea, albumin, pre-albumin, total
cholesterol, IL-6 and IGF-1) was tested in a logistic re-
gression model including SHERPA. We assessed the ac-
curacy of the predictive models in two ways. Discrimination
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– the ability to separate patients with or without disease –
was measured by the area under the receiver operating
characteristic (ROC) curve. ROC curves were compared
with the Hanley and McNeil method (21). Calibration – the
ability of the model to estimate the probability of a future
event correctly – was measured by comparing the average
predicted probability of the event in subgroups with the ob-
served proportion developing the event within those sub-
groups. We created four subgroups, with quartiles of es-
timated risk of functional decline (0 to <25%, 25 to
<50%, 50 to <75%, 75 to 100%). These subgroups
were determined both for SHERPA and the model in-
cluding SHERPA and biomarkers. For each subgroup,
mean predicted and mean actual functional decline rates
were calculated. The quality of calibration was assessed by
computing the Brier score, in which 0 implies perfect
prediction and 1 represents no predictive value (22).
The impact of primary medical diagnosis was also
tested in the logistic regression model including SHERPA.
Statistical analyses were performed by SPSS 15.0
software (SPSS Inc., Chicago, (Il), and ROC curves were




One hundred and eighteen patients were included.
Within 3 months of hospital discharge, 17 patients had
died. Since functional data at follow-up were missing for
three patients, 98 patients were included in the analyses
(mean age 81.8±5.2 yrs, 57% women, 16 resident in
nursing homes). The distribution of patients according to
the 3 selected diagnoses was: 31 with heart failure, 32
with hip fracture, and 35 with documented infection.
The median length of stay was 12 days [interquartile
range, IQ 8-19 days]. Three months after discharge,
functional decline had occurred in 46 patients (47%).
Table 1 lists baseline patient characteristics according
to the presence or absence of functional decline at 3
months. Patients with functional decline were 3 years old-
er than those who maintained functional status (p=0.002),
and had poorer pre-admission functional status (ADL
and IADL). There were no significant differences in gen-
der or comorbidity. The median length of stay was sig-
nificantly higher in patients who presented functional
decline at follow-up (13 days [IQ 10-24] vs 11 days [IQ
7.5-17], p=0.046). The rate of functional decline was sig-
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Functional decline
3 months after discharge
Yes No p-value
n= 46 n= 52
Clinical characteristics
Age (mean±SD) 83.6±5.6 80.2±4.3 0.002
Sex (% female) 65 50 ns
Comorbidity (CIRS-G), mean±SD
Total score 13.7±4.4 12.2±4.3 ns
Severity index 2.3±0.3 2.3±0.4 ns
Primary medical diagnosis, n (%) <0.001
Hip fracture 24 (75) 8 (25)
Heart failure 11 (35) 20 (65)
Infection 11 (31) 24 (69)
ADL, mean±SD 3.5±2.1 4.4±1.6 0.042
IADL, mean±SD 2.9±2.5 4.2±2.2 0.009
MMSE ( / 21), mean±SD 14.3±4.7 16.7±4.8 0.001
SHERPA (0-11.5), mean±SD 7.1±2.6 4.7±2.7 <0.001
Biological values, median (interquartile range)
CRP, mg/dL 11.7 (6.5-16.2) 9.8 (2.9-19.2) ns
Leucocytes, nbr/µL 8595 (7280-11780) 8615 (6765-10165) ns
Urea, mg/dL 44 (32-60) 43 (34.5-62) ns
Clearance, mL/min 46.6 (32.1-68.1) 50.0 (34.4-72.3) ns
Albumin, mg/dL 3083 (2605-3401) 3347 (2998-3595) ns
Pre-albumin, mg/dL 13 (10-14) 14 (11-20) ns
IL-6, pg/mL 98.6 (52.8-208.9) 60.4 (29.6-133.6) 0.019
IGF-1, ng/mL 155.5 (96.9-241.6) 204.2 (166.2-270.5) 0.002
CIRS-G: Cumulative Illness Rating Scale adapted for Geriatrics; ADL: activities of daily living; IADL: Instrumental ADL; MMSE: Mini Mental State Examina-
tion; SHERPA: Score Hospitalier d’Evaluation du Risque de la Perte d’Autonomie.
Table 1 - Baseline characteristics of study population.













nificantly higher for hip fracture patients than for the oth-
er patients (75% vs 33%, p<0.001). Table 2 lists the
comparison of functional evolution between the 3 sub-
groups. In univariate analyses of biological markers, IL-6
and IGF-1 were significantly different according to further
functional decline. IL-6 levels were significantly higher in
patients with hip fracture compared with the rest of the
cohort (data not shown).
Multivariate analyses
Logistic regression was used to select two biomarkers:
IL-6 and IGF-1. There was no correlation between these
two parameters (Spearman rho=-0.16).
SHERPA, IL-6 and IGF-1 were thus included in a
combined predictive model (SHERPA+). Areas under the
ROC curve and their confidence intervals [95% CI] were
0.79 [0.69-0.86] for SHERPA+ vs 0.73 [0.63-0.81] for
SHERPA alone (p=0.14) (Fig. 1). The logistic regression
equation proposed for risk calculation is:
f = (SHERPA / 4) + (IL-6 / 250) + (IGF-1 / 125) – 0.45
Brier scores were 0.185 and 0.213 for SHERPA and
SHERPA+ respectively, indicating a good predictive ca-
pacity within individual patients. Table 3 lists the cali-
bration of both models: with SHERPA+, the mean pre-
dicted probability of functional decline was very close to
the mean observed rate of decline within the four sub-
groups (determined by quartiles of estimated risk).
Since the risk of functional decline was higher in patients
with hip fracture, we tested the predictive value of these
biomarkers independently of disease status. When the
SHERPA+ model was challenged by including the diag-
nosis “hip fracture”, only SHERPA, IGF-1 and diagnosis
were significantly associated with functional decline. How-
ever, in the subgroup of patients with hip fracture, IL-6 and
IGF-1 were significantly associated with functional de-
cline (p-values respectively 0.049 and 0.028).
DISCUSSION
In this population of acutely ill hospitalized elderly, the
combination of proinflammatory and hormonal biomark-
ers (IL-6 and IGF-1) with a clinical screening tool (SHER-
PA) improved the accuracy of the prediction of func-
tional decline 3 months after hospitalization, compared
with SHERPA alone. Although the discriminative ability
of SHERPA+ (area under the ROC curve) only marginal-
ly improved, the composite model had better calibra-
tion performance, since the proportion of patients who ac-
tually underwent functional decline matched the aver-
age predicted risk of functional decline within the defined
subgroups. The added value of SHERPA+ to clinical
prediction may be due to better stratification of patients
at intermediate risk, as indicated by the calibration. The
question remains as to whether IL-6 and IGF-1 are directly
involved in the physiological pathway of functional decline,
or whether they are simply markers of the comorbid
process. In their hypothesized pathway to frailty, Walston
et al. emphasized the central role played by IL-6 and
IGF-1 in the impairment of various physiological sys-
tems, including muscle and the immune system (11).
Bautmans et al. did show that higher levels of inflamma-
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Admission diagnosis
ADL (mean±SD)
Pre-morbid Admission* Discharge* 3-month*
Heart failure (n=31) 4.4±1.7 3.6±2.1 4.0±1.9 4.1±1.9
Infection (n=35) 4.1±1.8 2.8±2.2 2.7±2.4 3.5±2.2
Hip fracture (n=32) 3.5±2.2 0.9±0.9 1.0±1.0 2.1±2.0
Total (n=98) 4.1±1.9 2.4±2.2 1.8±1.9 3.2±2.2
ADL: Activities of Daily Living (0 to 6); Pre-morbid: 2 weeks before admission; *p-value <0.05 for comparisons between 3 groups (Wilcoxon rank sum test).
Table 2 - Functional trajectories according to admission diagnosis.
Fig. 1 - Comparison of ROC for SHERPA and SHERPA+. SHER-
PA: Score Hospitalier d’Evaluation du Risque de la Perte
d’Autonomie; SHERPA+: Logistic regression model including
SHERPA, IL-6 and IGF-1; p-value for comparisons of AUC=0.14.
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tional characteristics for various SHERPA+ cut-offs. The
interaction between primary diagnosis, biomarkers and
functional decline in this study is a limitation, and the con-
tribution of the selected biomarkers to predict functional
decline should be tested in larger groups with various acute
disease conditions.
Another limitation is that our definition of functional de-
cline does not allow identification of the time-frame in
which patients develop this decline (before, during, or af-
ter hospitalization). However, these time-points have
been used in other cohort studies (5, 6), and consider the
event ‘hospitalization’ in a continuum of functional evo-
lution. Long-term perspectives are important in older
frail patients, since the impact of acute illness may become
apparent only after hospital discharge (27). At this stage,
the clinical application of SHERPA+ is limited. The two
biomarkers are more expensive than clinical assessment
with SHERPA and provide limited improvement of the
prediction of risk. However, the association of high levels
of IL-6 and low levels of IGF-1 is concordant with ob-
servations in community-dwelling patients.
Proper identification of frailty is a major public health
issue in providing adapted care to vulnerable hospitalized
elders. Clinical tools predicting functional decline, main-
ly based on physical or more comprehensive clinical cri-
teria, have shown only moderate discriminative ability, and
therefore inclusion of biological factors may improve
performance, as in the estimation of cardiovascular risk
(28). Further studies should include larger cohorts, and
combine several biomarkers in composite indexes.
Another perspective is that persistent changes in in-
flammatory and endocrine markers may be better pre-
dictors of functional decline than baseline measures, as has
been suggested in community-dwelling seniors (29), and
as shown in older patients hospitalized for pneumonia that
presented longer inflammatory activity compared with
younger patients (30), and the kinetics of inflammation
may be associated with functional reserves.
In conclusion, screening functional decline in hospi-
talized older patients may give an estimate of their frailty
tion were associated with significantly worse muscle func-
tion in geriatric hospitalized patients (23), which may at
least partly explain the functional impairment.
This study is one of the first addressing the potential of
selected biomarkers to improve clinical prediction of
functional prognoses for hospitalized elderly in unstable
medical condition. Until now, biomarkers have mainly
been associated with adverse functional outcomes in
community-dwelling patients, and little research has been
done in hospitalized elderly. In older patients hospitalized
for pneumonia, El Solh et al. studied the potential asso-
ciation of inflammatory markers with functional recovery
(24). In their cohort of 301 patients, TNF-alpha (but not
CRP) was associated with functional loss at the time of
hospital discharge. Inflammatory markers had no effect on
functional recovery 3 months after discharge (24). Formi-
ga et al. analysed serum IGF-1 levels in nonagenarian hos-
pitalized patients (n=60) and found that the decline in
ADL 3 months after discharge from hospital was not cor-
related with serum levels of IGF-1 on admission (25). Wu
et al. proposed a mathematical model predicting functional
decline 2 months after hospital discharge which included
measurement of albumin (10). This is convergent with the
fact that malnourished patients are more likely to present
functional decline 3 months after discharge (26). However,
our results did not confirm the influence of albumin.
There are several important limitations to these results.
The 3 subgroups of patients differed significantly in their
functional evolution. The predictive value of these
biomarkers is not independent of disease status. Indeed,
when admission diagnosis is included in the logistic re-
gression model SHERPA+, only IGF-1 remains signifi-
cantly associated with functional decline. Patients with hip
fracture should be considered as at high risk of func-
tional decline, and biomarkers have limited additional
predictive value. Further studies are needed to confirm our
results in a cohort representative of older patients admitted
through the emergency department. Due to the selection
of patients and the need for further validation, we do not
provide a new scoring scale or a table listing the opera-
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Subgroups
Probability SHERPA SHERPA + (IL-6 and IGF-1)
of FD (%) Patients (n) Predicted Actual Patients (n) Predicted Actual
FD rate (%) FD rate (%) FD rate (%) FD rate (%)
1 0-24 18 21 6 23 14 13
2 25-49 36 36 50 28 35 39
3 50-74 41 65 61 29 61 59
4 75-100 3 82 67 18 84 83
SHERPA: Score Hospitalier d’Evaluation du Risque de la Perte d’Autonomie; SHERPA+: SHERPA+IL-6 and IGF-1; FD: functional decline. Subgroups are based
on quartiles of estimated risk of FD for SHERPA and SHERPA+ explaining why number of patients in subgroups vary; 4 categories were determined: 0 to 25%,
25% to <50%, 50% to <75%, 75% to 100%. Predicted FD rate is mean predicted risk per subgroups with logistic model; actual FD rate is mean rate of FD
in each subgroup measured 3 months after discharge.
Table 3 - Comparison of predicted risks and observed rates of functional decline.













level. Targeting at-risk patients early after admission is a
prior issue, and selected biomarkers add limited predictive
value to SHERPA scores.
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